GentiBio is a technology company.
GentiBio has raised $160.0M across 1 funding round.
GentiBio has raised $160.0M in total across 1 funding round.
GentiBio is a clinical-stage biotherapeutics company developing engineered regulatory T cells (EngTregs) to treat autoimmune, alloimmune, and inflammatory diseases, including Type 1 Diabetes, IBD, SLE, MS, and acute tissue injury.[1][2][3][4] Its modular platform creates tissue-specific, stable, and scalable Tregs that suppress inflammation, restore immune tolerance, and potentially cure these conditions affecting hundreds of millions globally, serving patients underserved by systemic immunosuppressants.[2][4][6] The lead asset, GNTI-122, targets Type 1 Diabetes and is entering Phase 1 trials with readouts expected in 2026, backed by preclinical allogeneic programs and $20M seed funding from OrbiMed, Novartis Venture Fund, and RA Capital.[1][3][5]
GentiBio was founded in 2020 (some sources note 2019) in Cambridge, Massachusetts, by pioneers in Treg biology, synthetic immunology, and therapeutic development, including CEO and cofounder Dr. Adel Nada, Chandra Patel, and Andy Walker (current CEO).[1][3][5] The idea emerged from licensing Treg technologies from Seattle-based institutions like Seattle Children’s Research Institute, Benaroya Research Institute, and MIGAL Galilee Research Institute, addressing technical bottlenecks in Treg therapeutics such as IL-2 dependency and scalability.[1][2] Early traction came with a $20M seed round at launch, enabling platform integration for autologous and allogeneic EngTregs, with pivotal advancements in genome engineering and manufacturing.[1][4]
GentiBio stands out in the Treg field through its integrated platform resolving key hurdles:
GentiBio rides the cell therapy revolution in immunology, targeting the root cause of autoimmune diseases—dysregulated immune responses—amid a market shift from broad immunosuppressants to precise, curative modalities.[2][7] Timing aligns with advances in synthetic biology and CRISPR-enabled engineering, fueled by rising autoimmune prevalence (e.g., Type 1 Diabetes, IBD) and failures of prior Treg efforts due to instability and manufacturing.[1][6] Favorable forces include scalable allogeneic tech reducing costs versus personalized therapies, plus investor interest from biotech VCs, positioning GentiBio to influence the ecosystem by pioneering "reset" therapies that could expand to allergies, fibrosis, and beyond.[1][3][4]
GentiBio's near-term catalysts include GNTI-122 IND filing by June 2025 and 2026 Phase 1 readouts, with preclinical allogeneic assets advancing to candidates for IBD, SLE/MS, and tissue repair.[3][5] Trends like hypo-immune "off-the-shelf" cells and AI-optimized engineering will accelerate its path to commercialization, potentially disrupting a $100B+ autoimmune market. Its influence may evolve from early innovator to category leader, scaling EngTregs to replace risky chronic treatments—delivering on the promise of immunology therapeutics where natural Tregs fail.[2][4] This positions GentiBio as a high-momentum bet in precision immuno-engineering.
GentiBio has raised $160.0M in total across 1 funding round.
GentiBio's investors include Matrix Capital Management Company.
GentiBio has raised $160.0M across 1 funding round. Most recently, it raised $160.0M Series A in August 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2021 | $160.0M Series A | Matrix Capital Management Company |